Ligand Pharmaceuticals (LGND) FCF Margin (2010 - 2026)

Ligand Pharmaceuticals has disclosed FCF Margin across 17 years of filings, most recently posting 93.7% for Q1 2026.

• FCF Margin for Q1 2026 came in at 93.7%, up 15030.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 44.91% (up 1593.0% YoY), and the FY2025 annual result was 18.33%, down 3969.0% from the prior year.
• FCF Margin came in at 93.7% for Q1 2026 at Ligand Pharmaceuticals, up from 76.59% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 214.7% in Q3 2024 to a low of 148.53% in Q2 2024.
• The 5-year median for FCF Margin is 47.83% (2022), against an average of 45.78%.
• Across the five-year window, FCF Margin soared 19926 bps in 2024 and slumped 20299 bps in 2025, its largest moves.
• Ligand Pharmaceuticals' FCF Margin stood at 108.7% in 2022, then slumped by 63 bps to 39.75% in 2023, then jumped by 69 bps to 67.01% in 2024, then grew by 14 bps to 76.59% in 2025, then increased by 22 bps to 93.7% in 2026.
• The last three FCF Margin figures came in at 93.7% (Q1 2026), 76.59% (Q4 2025), and 11.71% (Q3 2025), per Business Quant data.